There are a number of possible side effects to using CBD oil, such as fatigue, dry mouth, lightheadedness, hypotension, and impaired motor functions. However, when used in moderate amounts, most people do not experience these side effects, and none of them are known for being fatal or particularly dangerous. More than 20,000 studies have been done in the past 15 years on cannabis, hemp, and cannabinoids, and the results have been overwhelmingly supportive of the therapeutic potential and viability of CBD oil. That being said, some people should be cautious before using this powerful oil.
Cannabis has always been a popular form of treatment for a variety of medical conditions, but in the 1930’s growing concerns about the dangers of marijuana abuse led to cannabinoids being banned. A century has past and despite all efforts from cannabis enthusiasts through social media channels and online media, cannabis is still classed as a schedule 1 drug.
Due to the anti-inflammatory properties of cannabidiol, insulin resistance (the chief metabolic problem for patients with type 2 diabetes) is reduced, leading to a better prognosis thanks also to the lower incidence of dead tissue. Ever since the discovery of CBD in the 1990’s, speculation existed to its effect on other types of receptors (not just cannabinoid receptors) which could be manipulated and included in the treatment of some cardiovascular diseases like atherosclerosis. In light of these speculations, researchers at the University of Tel Aviv (walking in the footsteps of the “father” of cannabinoid research, Dr. Raphael Mechoulam) demonstrated a 30 percent blood flow increase in rodents with areas of dead tissue in the heart muscle.
The inquiry upon the manner in which THC produces its psychoactive effects on the human body led, in the 1980’s, to the discovery of the endocannabinoid system – a rather loose complex of nerve receptors which under the influence of compounds called cannabinoids trigger many physiological and psychological reactions. Because cannabinoid receptors are present in almost every tissue of a mammal’s body (although they are not limited to mammals), it has wide-ranging influences on the well-being of an organism. Therefore cannabinoids are definitely substances that deserve further attention from scientists.
The anxiolytic effect of THC is well documented, with other cannabinoids (especially CBD) also providing relief (if less potent). The exact pathways of the process have not been identified. A preliminary study published in 2013 in the International Neuropsychopharmacology Journal has set the foundations for further research linking CBD to future treatments for depression and psychosis.
A study published by David Cheng, Postdoctoral Scientist, Neuroscience Research, University of New South Wales, NSW, Australia, says that CBD has a potential as a preventive measure against symptoms of Alzheimer’s. This presents yet another exciting development for medical researchers, given the persistent challenges to finding effective solutions for this condition.
While overstimulation of the CB1 receptor may lead to symptoms such as high blood pressure and abnormally high cholesterol levels, CBD is a CB1 antagonist, so it is not likely to cause such issues. Furthermore, the World Health Organization has recently issued a global report on CBD, claiming that it has a good safety profile and minimal adverse public health effects.
This isn’t new but had to be mentioned. One of the major and well-known benefits of cannabis is its ability to treat pain and helping with pain management. It has the capabilities of assisting with chronic pain as well as inflammation. Furthermore, it has been found to help patients deal with severe rheumatism and arthritis as well as other chronic pains.
Moreover, Murray Mittleman, an associate professor of medicine at Harvard Medical School, explained to Time Magazine in 2013 that weed users had lower fasting insulin levels and were less resistant to insulin produced by the body. He was referring to research from the National Health and Nutrition Examination Survey, which analyzed 4,600 men and women over a five year period from 2005 to 2010. 48% of them used marijuana at least once in their lives, and 12% were current weed users.
More recent experiments, involving the administration of a part CBD part THC solution, have yielded results that contradict the first supposition. At present, on the evidence that cannabidiol reduces some of the psychoactive effects of tetrahydrocannabinol (acting as a de facto antidepressant), scientists argue that cannabidiol has a holistic but indirect influence on all cannabinoid receptors in the endocannabinoid system. The main consequence of this impact seems to be an increase in the production of endocannabinoids. This is now the prevailing idea that accounts for the mountains of empirical evidence of how the benefits of cannabidiol are expressed at the cellular level.